切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2009, Vol. 03 ›› Issue (06) : 642 -650. doi: 10.3877/cma.j.issn.1674-0807.2009.06.008

实验研究

转基因溶瘤性单纯疱疹病毒对人类乳腺癌的治疗作用
王佳妮1, 刘仁斌1,(), 李俊杰1, Mohamed Abdalwali·Thabit1, Samuel D.Rabkin2   
  1. 1.510630 广州,中山大学附属第三医院乳腺疾病诊治中心
    2.02114 波士顿,美国哈佛大学麻省总医院分子外科实验室
  • 收稿日期:2009-06-30 出版日期:2009-12-01
  • 通信作者: 刘仁斌
  • 基金资助:
    国家自然科学基金资助项目(30672410)广州市科技局国际合作项目(2007Z3-I0021)

Oncolytic herpes simplex virus vectors for the treatment of human breast cancer

Jia-ni WANG1, Ren-bin LIU,1(), Jun-jie LI1, Abdalwali·Thabit Mohamed1, D.Rabkin Samuel1   

  1. 1.Breast Disease Center,Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510630,China
  • Received:2009-06-30 Published:2009-12-01
  • Corresponding author: Ren-bin LIU
引用本文:

王佳妮, 刘仁斌, 李俊杰, Mohamed Abdalwali·Thabit, Samuel D.Rabkin. 转基因溶瘤性单纯疱疹病毒对人类乳腺癌的治疗作用[J/OL]. 中华乳腺病杂志(电子版), 2009, 03(06): 642-650.

Jia-ni WANG, Ren-bin LIU, Jun-jie LI, Abdalwali·Thabit Mohamed, D.Rabkin Samuel. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(06): 642-650.

目的

通过观察溶瘤性单纯疱疹病毒(HSV)载体G47Δ对人类乳腺癌细胞系SK-BR-3、MDA-MB-453和MDA-MB-231的细胞毒效应,探讨其对人乳腺癌的治疗作用。

方法

体外培养人乳腺癌细胞SK-BR-3、MDA-MB-453和MDA-MB-231,将G47Δ按不同滴度(MOI)加入培养液中,每天观察细胞的生长状态。G47Δ含有LacZ基因,其在被感染细胞中的表达可用X-gal染色检测。

结果

较低MOI(0.01)的G47Δ对SK-BR-3和MDA-MB-453具有较高的毒性,但对MDA-MB-231没有杀伤作用。在MOI=0.01的实验组,感染病毒后第5天,超过90%的SK-BR-3和MDA-MB-453细胞已被杀灭;但在MOI=0.01组及MOI=0.10组,MDA-MB-231感染G47Δ后细胞数量与对照组相比均无差异。采用X-gal染色证实了病毒在癌细胞中复制和传播。

结论

近期构建的HSV载体-G47Δ可有效杀灭人乳腺癌细胞SK-BR-3和MDAMB-453,但未显示出对MDA-MB-231的影响。G47Δ的有效性及缺陷为新型溶瘤性单纯疱疹病毒G47Δ用于乳腺癌治疗的临床试验提供有力依据,但其应用尚需进一步研究。

Objective

To investigate the efficacy of herpes simplex virus(HSV)vector,G47Δfor the treatment of the human breast cancer through the observation of its cytotoxicity on three human breast cancer cell lines,SK-BR-3,MDA-MB-453 and MDA-MB-231.

Methods

Human breast cancer SK-BR-3,MDAMB-453 and MDA-MB-231 cells were cultured and inoculated with G47Δof different multiplicities of infection(MOI).The cytotoxicity was observed every day.G47Δ contained the LacZ gene,whose expression in infected cells was detected with X-gal histochemistry.

Results

G47Δwas highly cytotoxic for SK-BR-3 and MDA-MB-453 cells in vitro at very low MOI(0.01),but no efficiency was observed in MDA-MB-231 cells.X-gal staining of infected tumor cells in vitro illustrated the replication and spread of the virus.In the MOI=0.01 group,on the fifth day after infection,more than 90%SK-BR-3 and MDA-MB-453 cells were killed,but after MDA-MB-231 was infected,in the MOI=0.01 and MOI=0.10 groups,the cell number was similar to the mock.

Conclusions

Recently constructed oncolytic HSV vector G47Δwas effective at killing human breast cancer SK-BR-3 and MDA-MB-453 cells in vitro,but did not influence the growth of MDA-MB-231.The efficiency and deficiency of this novel cancer therapy warrants further investigation and consideration of clinical application.

图1 G47Δ对SK-BR-3细胞的毒性效应 a:MOI=0.01;b:MOI=0.10;细胞培养于37℃,含1%灭活胎牛血清的DMEM,感染后第1~5天计数细胞,纵轴为感染后细胞所占当日无感染对照组细胞数的百分比。
图2 SK-BR-3细胞感染G47Δ后不同时间的X-gal染色结果(×200) 细胞培养于37℃、含1%灭活胎牛血清的DMEM,感染后第1~5天分别用固定液处理,X-gal工作液染色,中性红复染,感染G47Δ病毒的细胞表达LacZ,被X-gal染成蓝色。
图3 G47Δ对MDA-MB-453细胞的毒性效应 a:MOI=0.01;b:MOI=0.10;细胞培养于37℃、含1%灭活胎牛血清的DMEM,感染后第1~5天计数细胞,纵轴为感染后细胞所占当日无感染对照组细胞数的百分比。
图4 MDA-MB-453细胞感染G47Δ后不同时间的X-gal染色结果(×200) 细胞培养于37℃、含1%灭活胎牛血清的DMEM,感染后第1~5天分别用固定液处理,X-gal工作液染色,中性红复染,感染G47Δ病毒的细胞表达LacZ,被X-gal染成蓝色。
图5 G47Δ对MDA-MB-231细胞的毒性效应 a:MOI=0.01;b:MOI=0.10;细胞培养于37℃,含1%灭活胎牛血清的RPMI-1640,感染后第1~5天计数细胞。纵轴为感染后细胞所占当日对照组细胞的百分比。
图6 MDA-MB-231细胞感染G47Δ后不同时间的X-gal染色结果(×200) 细胞培养于37℃、含1%灭活胎牛血清的DMEM,感染后的第1~5天分别用固定液处理,X-gal工作液染色,中性红复染,感染G47Δ病毒的细胞表达LacZ,被X-gal染成蓝色。
[1]
Simeone A M,Broemeling L D,Rosenblum J,et al.HER-2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide(4-HPR)in breast cancer cells by decreasing nitric oxide production.Oncogene,2003,10:6739-6747.
[2]
Mineta T,Rabkin S D,Yazaki T,et al.Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.Nat Med,1995,1:938-943.
[3]
Hunter W D,Martuza R L,Feiganbaum F,et al.Attenuated,replication-competent herpes simplex virus type 1 mutant G207:safety evaluation of intracerebral injection in nonhuman primates.J Virol,1999,73:6319-6326.
[4]
Markert J M,Medlock M D,Rabkin S D,et al.Conditionally replicating herpes simplex virus mutant,G207 for the treatment of malignant glioma:results of a phase I trial.Gene Ther,2000,7:867-874.
[5]
Varghese S,Rabkin S D.Oncolytic herpes simplex virus vectors for cancer virotherapy.Cancer Gene Ther,2002,9:967-978.
[6]
Kim D,Martuza R L,Zwiebel J.Replication-selective virotherapy for cancer:Biological principles,risk management and future directions.Nat Med,2001,7:781-787.
[7]
Todo T."Armed"oncolytic herpes simplex viruses for brain tumor therapy.Cell Adhesion&Migration,2008,2:208-213.
[8]
Liu R,Varghese S.Rakbin S D.The treatment of C3(1)/Tag transgenic mouse breast cancer with HSV.Cancer Research,2005,64:541-549.
[9]
Liu R,Martuza R L,Rakbin S D.Intracarotid delivery of G47Δto intracerebral tumors after blood brain barrier disruption.Gene Therapy,2005,12:280-288.
[10]
Liu R,Rabkin S D.HSV for the treatment of human breast cancer.Chinese Medical Journal,2005,30:225-229.
[11]
Cozzi P J,Malhotra S,Mc Auliffe P,et al.Intravesical oncolytic viral therapy using attenuated replication-competent herpes simplex viruses G207 and NV1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.FASEB J,2001,15:1306-1308.
[12]
Delman K A,Bennett JJ,Zager JS,et al.Effects of preexisting immunity on the response to herpes simplex-based oncolytic virus therapy.Hum Gene Ther,2000,11:2465-2472.
[13]
Bennett J J,Delman K A,Burt B M,et al.Comparison of safety,delivery,and efficacy of two oncolytic herpes simplex virused(G207 and NV1020)for peritoneal cancer.Cancer Gene Ther,2002,9:935-945.
[14]
Cozzi P J,Burke P B,Bhargav A,et al.Oncolytic viral gene therapy for prostate cancer using two attenuated,replicationcompetent,genetically engineered herpes simplex virus.Prostate,2002,53:95-100.
[15]
Dock G.Rabies virus vaccination in a patient with cervical carcinoma.Am J Med Sci,1904,127:563.
[16]
DePace N.Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica.Ginecologia,1912,9:82-89.
[17]
Sinkovics J,Horvath J.New developments in the virus therapy of cancer:a historical review.Intervirology,1993,36:193-214.
[18]
Kirn D H.Replicating oncolytic viruses:an overview.Expert Opin Investig Drugs,1996,5:753-762.
[19]
Kirn D,Niculescu Duvaz I,Hallden G,et al.The emerging fields of suicide gene therapy and virotherapy.Trends Mol Med,2002,8:S68-S73.
[20]
Shen W,Wang C Y,Wang X H,et al.Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo.J Exp Clin Cancer Res,2009,28:81.
[21]
Wodarz D,Komarova N.Towards Predictive Computational Models of Oncolytic Virus Therapy:Basis for Experimental Validation and Model Selection.PLoS ONE,2009,4:e4271.
[22]
Rabkin SD,Hernaiz Driever P.Replication-competent herpes simplex virus vectors for cancer therapy.Monogr Virol Basel Karger,2001,22:1-45.
[23]
Martuza R L.Conditionally replicating herpes vectors for cancer therapy.J Clin Invest,2000,105:841-846.
[24]
Liu R B,Samuel D.Rabkin.Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.Chinese Medical Journal,2005,118:307-312.
[25]
Cornfield D B,Palazzo J P,Schwartz G F,et al.The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast:a study of a large cohort of patients treated with surgery alone.Cancer,2004,100:2317-2327.
[26]
邱晓光,李双兰,蒲庆田,等.端粒酶活性、c-erbB-2的表达及对乳癌早期癌变的诊断价值.中国肿瘤生物治疗杂志,2002,9:143.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要